The market for GLP-1 drugs is undergoing changes, including a pill form, a stronger injectable application, and more cash payment options[1]. The first GLP-1 tablet for obesity, Novo Nordisk's Wego semaglutide tablets, hit the shelves[3]. An introductory dose of 1.5 mg costs $149 per month, stronger variants of 9 mg and 25 mg cost $299, and a 4 mg dose will increase in price to $199 starting April 15[3]. The tablet form offers an alternative for patients who do not want injections and brings more flexibility in treatment[3]. Production is in North Carolina with prior supply to avoid outages like 2024[3]. Novo Nordisk hopes the tablets will regain the lead over competition from Eli Lilly, whose Zepbound overtook Wego's in prescriptions in 2025[3]. Eli Lilly is planning its own tablet drug orforglipron as a more affordable alternative, with a possible launch in 2026 after FDA approval[2]. Drug for hypercortisolism refused[original content].